Does dual trigger improve euploidy rate in normoresponder? A cross-sectional study.
Aneuploidy.
Chorionic gonadotropin
Preimplantation screening
Gonadotropin-releasing hormone
Journal
International journal of reproductive biomedicine
ISSN: 2476-4108
Titre abrégé: Int J Reprod Biomed
Pays: Iran
ID NLM: 101679102
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
09
07
2022
revised:
08
10
2022
accepted:
16
04
2023
medline:
26
6
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
With the introduction of the dual triggering-gonadotropin-releasing hormone (GnRH) analog and recombinant human chorionic gonadotropin (hCG) combination, women with a history of low mature oocyte proportion and empty follicle syndrome were shown to benefit from the dual trigger. To investigate whether dual triggering of oocyte maturation with a GnRH agonist (GnRHa) combined with hCG can affect the euploidy rate and improve in vitro fertilization outcomes for normoresponder women. In this cross-sectional study, 494 women who underwent controlled ovarian stimulation with hCG (n = 274) or dual triggering (hCG+GnRHa, n = 220) at Acibadem Maslak hospital, Assisted Reproductive Unit, from January 2019-2022 were enrolled in this study. Preimplantation genetic testing for aneuploidy was performed on all participants. Both groups had similar baseline and clinical characteristics. Of the 881 embryos biopsied, 312 (35.4%) were reported as euploid in the hCG trigger group; in the dual trigger group, 186 (29.8%) of 623 screening embryos were reported as euploid. The hCG group had a higher euploidy rate per biopsied embryo, although the difference was not statistically significant (31.4 In normoresponders, adding GnRHa for final follicular maturation to hCG did not improve the euploidy rate.
Sections du résumé
Background
UNASSIGNED
With the introduction of the dual triggering-gonadotropin-releasing hormone (GnRH) analog and recombinant human chorionic gonadotropin (hCG) combination, women with a history of low mature oocyte proportion and empty follicle syndrome were shown to benefit from the dual trigger.
Objective
UNASSIGNED
To investigate whether dual triggering of oocyte maturation with a GnRH agonist (GnRHa) combined with hCG can affect the euploidy rate and improve in vitro fertilization outcomes for normoresponder women.
Materials and Methods
UNASSIGNED
In this cross-sectional study, 494 women who underwent controlled ovarian stimulation with hCG (n = 274) or dual triggering (hCG+GnRHa, n = 220) at Acibadem Maslak hospital, Assisted Reproductive Unit, from January 2019-2022 were enrolled in this study. Preimplantation genetic testing for aneuploidy was performed on all participants.
Results
UNASSIGNED
Both groups had similar baseline and clinical characteristics. Of the 881 embryos biopsied, 312 (35.4%) were reported as euploid in the hCG trigger group; in the dual trigger group, 186 (29.8%) of 623 screening embryos were reported as euploid. The hCG group had a higher euploidy rate per biopsied embryo, although the difference was not statistically significant (31.4
Conclusion
UNASSIGNED
In normoresponders, adding GnRHa for final follicular maturation to hCG did not improve the euploidy rate.
Identifiants
pubmed: 37362090
doi: 10.18502/ijrm.v21i5.13473
pmc: PMC10285196
doi:
Types de publication
Journal Article
Langues
eng
Pagination
395-402Informations de copyright
Copyright © 2023 Yildirim Kopuk et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
Syst Biol Reprod Med. 2021 Feb;67(1):42-49
pubmed: 33406906
Reprod Biomed Online. 2020 Jun;40(6):887-893
pubmed: 32389425
Fertil Steril. 2016 Sep 1;106(3):653-659.e1
pubmed: 27341989
Biomed Res Int. 2014;2014:580171
pubmed: 25133168
J Assist Reprod Genet. 2021 Jun;38(6):1419-1427
pubmed: 33661465
Gynecol Endocrinol. 2019 Jul;35(7):628-630
pubmed: 30810400
Eur J Obstet Gynecol Reprod Biol. 2017 Nov;218:92-98
pubmed: 28957685
J Clin Endocrinol Metab. 1990 Oct;71(4):918-22
pubmed: 2119392
Hum Reprod. 2012 May;27(5):1357-67
pubmed: 22357773
Fertil Steril. 2008 Jul;90(1):231-3
pubmed: 17981269
Hum Reprod. 2011 Jan;26(1):76-81
pubmed: 20961941
Reprod Sci. 2022 Aug;29(8):2265-2271
pubmed: 35476351
Fertil Steril. 2017 Jun;107(6):1323-1328.e2
pubmed: 28501366
Fertil Steril. 2013 Nov;100(5):1296-302
pubmed: 23993928
J Assist Reprod Genet. 2020 Aug;37(8):1939-1948
pubmed: 32533431
Gynecol Endocrinol. 2015 Feb;31(2):145-7
pubmed: 25385007
J Ovarian Res. 2015 Aug 21;8:60
pubmed: 26293447
Hum Reprod. 2020 Jul 1;35(7):1648-1654
pubmed: 32563188
J Ovarian Res. 2014 Aug 02;7:77
pubmed: 25296696
Reprod Sci. 2021 Dec;28(12):3390-3396
pubmed: 34076872
Endocr Rev. 2018 Oct 1;39(5):593-628
pubmed: 29982525
Fertil Steril. 2014 Aug;102(2):405-9
pubmed: 24842671
Facts Views Vis Obgyn. 2014;6(4):203-9
pubmed: 25593695
Front Endocrinol (Lausanne). 2020 Oct 06;11:537205
pubmed: 33123084
World J Clin Cases. 2020 Feb 26;8(4):825-830
pubmed: 32149067
Fertil Steril. 2019 Aug;112(2):258-265
pubmed: 31103285
Fertil Steril. 2011 May;95(6):2034-8
pubmed: 21377153
Reprod Med Biol. 2022 Feb 04;21(1):e12440
pubmed: 35386366
Cochrane Database Syst Rev. 2014 Oct 31;(10):CD008046
pubmed: 25358904